TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: left SLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: right SLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2max improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: B-PHQ-9 self-assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Communication about pain concerns
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Full recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major amputations
Endpoint domain: Adverse events/effects
Primary endpoint: Wound closure speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: HLA antigen association with pseudoexfoliation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Performance on the OSCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall satisfaction with the course
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Risk of hypoperfusion and avascular segment necrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in dizziness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of facial rhytids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of RECOVERY
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of rupture
Endpoint domain: Mortality/survival
Primary endpoint: Number of patients hospitalised
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean number of hospitalisations per patient
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean number of hospitalisation days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Reduction in proportion of participants with unhealthy diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in aerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving at least 5% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Febrile neutropenia rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients symptom free after 10 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Non-patency rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Septic complications
Endpoint domain: Adverse events/effects
Primary endpoint: Total lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T-helper cells (CD4+) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of ER-positive samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recall error of age at alcohol use onset
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of return for the follow-up visit
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean nightly CPAP use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of guideline-recommended therapies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visualisation rate of bone scintigraphy and FDG-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of bone scintigraphy and FDG-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: specificity of bone scintigraphy and FDG-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores for seasonal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of rescue antiallergic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: word learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in nose and head
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Night sleeping
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Pain experienced by patients
Endpoint domain: Adverse events/effects
Primary endpoint: Dissatisfaction with treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Unsuccessful treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Mean number of mature oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cancelled cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ovarian hyperstimulation syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in skin pores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in area under the plasma concentration‐time curve for omeprazole, tolbutamide, and midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: picture recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adjusted death, myocardial infarction, or revascularization
Endpoint domain: Mortality/survival
Primary endpoint: adjusted death or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: adjusted death
Endpoint domain: Mortality/survival
Primary endpoint: bacterial biofilm growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: surface deformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TTO score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SG score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: level of motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of posttraumatic stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptoms of prolonged grief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Recovery rates for PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SVR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: E/Ea ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: exercise time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of ventricular arrhythmias
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic bioequivalence (AUC0-t, AUC0-∞, Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic bioequivalence (ANC AUEC0-t, Emax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of cold stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diurnal pattern of core temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total neuropsychologic change scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of cerebral microembolization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Proportion of informed choices
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Taste rating of oral antibiotic formulations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Baseline Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back-related function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back pain intensity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karnofsky Performance Status (KPS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Methylation rate of MGMT genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxic/adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: PTSD prevalence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: frequency and severity of reported adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Blood glucose levels at <110 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of patients reporting discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of patients reporting adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Cervical resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Force required to dilate the cervix
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: highest pain scores 1 hour postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBGI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain scores on VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of any breastfeeding at 4 and 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of full breastfeeding at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sero-response to the candidate vaccine strain NZ98/254
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: diagnostic accuracy for detecting erosive esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reduction in pain after 20 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disability level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: average pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: worst pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Expression of caspase 3 in endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity subscale of the Eyberg child behaviour inventory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to treatment for perianal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pneumococcal geometric mean antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mild injection-site redness and swelling
Endpoint domain: Adverse events/effects
Primary endpoint: sE-selectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hepatic glucose production rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Free fatty acids levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in LV end-systolic volume (LVESV) by >15%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in cardiac output (CO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: eradication rates for Pseudomonas aeruginosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: pain severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Improved outcome for the perineum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: percent change of plaque volume (PV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percent change of lipid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean hot flash score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vaginal health index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse rate after remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute mean tissue concentration of PGE(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to solve case studies
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Use of unnecessary diagnostic tests
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: cyclosporine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: graft rejection episodes
Endpoint domain: Adverse events/effects
Primary endpoint: upper limb motor functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 12-week readmission rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: any sleep problem
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Mean distance on the 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAM10 protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAM15 protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAM/integrin ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion independence for 8 weeks or longer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adequate samples for histologic evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cellularity of samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of DGE
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of pancreatic fistula
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial plasma glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median Survival Time
Endpoint domain: Mortality/survival
Primary endpoint: 10-year RR for major osteoporotic fractures
Endpoint domain: Mortality/survival
Primary endpoint: 10-year RR for hip fractures
Endpoint domain: Mortality/survival
Primary endpoint: Alkalinizing effect duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum potassium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum sodium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDS score improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion with depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: acute procedural pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with the procedure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain control on postoperative day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxycodone consumption at 24 hours postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained smoking abstinence for at least 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posttreatment concentrations of E(1) and E(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Increased cancer risk associated with high concentrations of E(1) and E(2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Global Aesthetic Improvement Scale (GAIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to perform tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Needle control improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant satisfaction with device
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: TEWL improvement ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: VAS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Amplitude of pupil constriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time constant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h urine sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: graft volume decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average pocket depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insomnia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anxiety score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: depression score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of TNF-alpha and IL-1beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NDS (Nervous Disability Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BI (Barthel Index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Decrease in acne scars grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patients' satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of viable bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: IGF‐1 SD score increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in visceral adipose tissue (VAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in mitochondrial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montgomery‐Asberg Depression Rating Scale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score <5 at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LANSS score <12 at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative prediction of extracapsular tumor invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incremental cost per life year saved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Gestational age at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of latency period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-assessed certainty
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: redistributed plantar pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of symptom medication scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in serum levels of DP-specific IgE Abs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cardiovascular outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical cure rate of toenails
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative mycological examination findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes